
	構造検索構造検索の利用方法	構造ファイル取込 MOLfileがご利用頂けます。 (V3000形式はご利用頂けません）完全一致検索部分構造検索 (substructure) 部分構造検索 (superstructure) 部分構造検索 (sub, super) 類似構造検索

研究者

J-GLOBAL ID：200901038338149757 更新日: 2025年03月10日

長谷川幸清

HASEGAWA Kosei

所属機関・部署：
職名：教授
ホームページURL (1件)： http://www.saitama-med.ac.jp/kokusai/fujinshuyo/
競争的資金等の研究課題 (6件)：

全件表示

論文 (85件)：

Ishida M, Sato S, Sato I, Yoshioka A, Uchida N, Mizunuma N, Hasegawa K, Onishi H. What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder. Palliat Support Care. 2024
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncol. 2024
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, et al. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. JGO. 2024
Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, et al. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. Oncologist. Oncologist. 2024
Isoda L, Sonoda-Fukuda E, Fujino H, Takarada T, Hasegawa K, Kasahara N, Kubo S. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Res. 2023

講演・口頭発表等 (24件)：

HDAC6 as a therapeutic target for ovarian clear cell carcinoma, in association with ARID1A loss
(17th Biennial Meeting of the International Gynecologic Cancer Society 2018)
Soluble folate receptor alpha as a biomarker for epithelial ovarian cancer
(72th Japanese Cancer Association 2013)
Redirected antitumor activity of an engineered Sendai virus vector in ovarian cancer cells
(AACR/JCA 2013)
Tumor Board I: Clear cell carcinoma of the uterus
(14th Biennial Meeting of the International Gynecologic Cancer Society 2012)
Soluble MUC1 as a Biomarker for Epithelial Ovarian Cancer
(14th Biennial Meeting of the International Gynecologic Cancer Society 2012)

学歴 (2件)：

学位 (2件)：

経歴 (8件)：

全件表示

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。


	フリーワード	※以下の同義語を加えると、ヒット件数を増やすことができます。




		～

長谷川 幸清